Literature DB >> 23775312

Mitosis as an anti-cancer drug target.

Anna-Leena Salmela1, Marko J Kallio.   

Abstract

Suppression of cell proliferation by targeting mitosis is one potential cancer intervention. A number of existing chemotherapy drugs disrupt mitosis by targeting microtubule dynamics. While efficacious, these drugs have limitations, i.e. neuropathy, unpredictability and development of resistance. In order to overcome these issues, a great deal of effort has been spent exploring novel mitotic targets including Polo-like kinase 1, Aurora kinases, Mps1, Cenp-E and KSP/Eg5. Here we summarize the latest developments in the discovery and clinical evaluation of new mitotic drug targets.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23775312     DOI： 10.1007/s00412-013-0419-8

Source DB:  PubMed          Journal:  Chromosoma        ISSN： 0009-5915            Impact factor:   4.316


  262 in total

Review 1.  Chromosome segregation and cancer: cutting through the mystery.

Authors:  P V Jallepalli; C Lengauer
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

Review 2.  HDAC modulation and cell death in the clinic.

Authors:  Carmela Dell'Aversana; Ilaria Lepore; Lucia Altucci
Journal:  Exp Cell Res       Date:  2012-02-03       Impact factor: 3.905

Review 3.  Is the focus moving toward a combination of targeted drugs?

Authors:  Steven Grant
Journal:  Best Pract Res Clin Haematol       Date:  2008-12       Impact factor: 3.020

4.  Induction of apoptosis by monastrol, an inhibitor of the mitotic kinesin Eg5, is independent of the spindle checkpoint.

Authors:  Gregory M Chin; Ronald Herbst
Journal:  Mol Cancer Ther       Date:  2006-10       Impact factor: 6.261

5.  Risks of leukaemia and solid tumours in individuals with Down's syndrome.

Authors:  H Hasle; I H Clemmensen; M Mikkelsen
Journal:  Lancet       Date:  2000-01-15       Impact factor: 79.321

6.  Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Authors:  Arijit Chakravarty; Vaishali Shinde; Josep Tabernero; Andres Cervantes; Roger B Cohen; E Claire Dees; Howard Burris; Jeffrey R Infante; Teresa Macarulla; Elena Elez; Jordi Andreu; Edith Rodriguez-Braun; Susana Rosello; Margaret von Mehren; Neal J Meropol; Corey J Langer; Bert ONeil; Douglas Bowman; Mengkun Zhang; Hadi Danaee; Laura Faron-Yowe; Gary Gray; Hua Liu; Jodi Pappas; Lee Silverman; Chris Simpson; Bradley Stringer; Stephen Tirrell; Ole Petter Veiby; Karthik Venkatakrishnan; Katherine Galvin; Mark Manfredi; Jeffrey A Ecsedy
Journal:  Cancer Res       Date:  2010-12-10       Impact factor: 12.701

7.  AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis.

Authors:  Robert W Wilkinson; Rajesh Odedra; Simon P Heaton; Stephen R Wedge; Nicholas J Keen; Claire Crafter; John R Foster; Madeleine C Brady; Alison Bigley; Elaine Brown; Kate F Byth; Nigel C Barrass; Kirsten E Mundt; Kevin M Foote; Nicola M Heron; Frederic H Jung; Andrew A Mortlock; F Thomas Boyle; Stephen Green
Journal:  Clin Cancer Res       Date:  2007-06-15       Impact factor: 12.531

8.  AZD1152, a novel and selective aurora B kinase inhibitor, induces growth arrest, apoptosis, and sensitization for tubulin depolymerizing agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo.

Authors:  Jing Yang; Takayuki Ikezoe; Chie Nishioka; Taizo Tasaka; Ayuko Taniguchi; Yoshio Kuwayama; Naoki Komatsu; Kentaro Bandobashi; Kazuto Togitani; H Phillip Koeffler; Hirokuni Taguchi; Akihito Yokoyama
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

9.  Improved grading of breast adenocarcinomas based on genomic instability.

Authors:  Ulrike Kronenwett; Sören Huwendiek; Carin Ostring; Neil Portwood; Uwe J Roblick; Yudi Pawitan; Ayodele Alaiya; Roland Sennerstam; Anders Zetterberg; Gert Auer
Journal:  Cancer Res       Date:  2004-02-01       Impact factor: 12.701

10.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Kristan A Meetze; Suresh K Balani; Olga Burenkova; Wei Chen; Katherine M Galvin; Kara M Hoar; Jessica J Huck; Patrick J LeRoy; Emily T Ray; Todd B Sells; Bradley Stringer; Stephen G Stroud; Tricia J Vos; Gabriel S Weatherhead; Deborah R Wysong; Mengkun Zhang; Joseph B Bolen; Christopher F Claiborne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-23       Impact factor: 11.205
View more
  22 in total

1.  A biosensor-based approach reveals links between efflux pump expression and cell cycle regulation in pleiotropic drug resistance of yeast.

Authors:  Jian Li; Kristen Kolberg; Ulrich Schlecht; Robert P St Onge; Ana Maria Aparicio; Joe Horecka; Ronald W Davis; Maureen E Hillenmeyer; Colin J B Harvey
Journal:  J Biol Chem       Date:  2018-12-04       Impact factor: 5.157

Review 2.  Targeting mitotic pathways for endocrine-related cancer therapeutics.

Authors:  Shivangi Agarwal; Dileep Varma
Journal:  Endocr Relat Cancer       Date:  2017-06-14       Impact factor: 5.678

Review 3.  Critical role of mitosis in spontaneous late-onset Alzheimer's disease; from a Shugoshin 1 cohesinopathy mouse model.

Authors:  Chinthalapally V Rao; Mudassir Farooqui; Adam S Asch; Hiroshi Y Yamada
Journal:  Cell Cycle       Date:  2018-09-20       Impact factor: 4.534

4.  Phosphorylation of SAF-A/hnRNP-U Serine 59 by Polo-Like Kinase 1 Is Required for Mitosis.

Authors:  Pauline Douglas; Ruiqiong Ye; Nicholas Morrice; Sébastien Britton; Laura Trinkle-Mulcahy; Susan P Lees-Miller
Journal:  Mol Cell Biol       Date:  2015-05-18       Impact factor: 4.272

5.  S-trityl-L-cysteine, a novel Eg5 inhibitor, is a potent chemotherapeutic strategy in neuroblastoma.

Authors:  Wei Wu; Shao Jingbo; Weijue Xu; Jiangbin Liu; Yiming Huang; Qingfeng Sheng; Zhibao Lv
Journal:  Oncol Lett       Date:  2018-05-21       Impact factor: 2.967

Review 6.  Hitting the brakes: targeting microtubule motors in cancer.

Authors:  Gayathri Chandrasekaran; Péter Tátrai; Fanni Gergely
Journal:  Br J Cancer       Date:  2015-07-16       Impact factor: 7.640

7.  Midostaurin preferentially attenuates proliferation of triple-negative breast cancer cell lines through inhibition of Aurora kinase family.

Authors:  Masaaki Kawai; Akio Nakashima; Shinji Kamada; Ushio Kikkawa
Journal:  J Biomed Sci       Date:  2015-07-04       Impact factor: 8.410

Review 8.  An overview of the spindle assembly checkpoint status in oral cancer.

Authors:  José Henrique Teixeira; Patrícia Manuela Silva; Rita Margarida Reis; Inês Moranguinho Moura; Sandra Marques; Joana Fonseca; Luís Silva Monteiro; Hassan Bousbaa
Journal:  Biomed Res Int       Date:  2014-06-03       Impact factor: 3.411

9.  Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes.

Authors:  Minako Imamura; Atsushi Takahashi; Toshimasa Yamauchi; Kazuo Hara; Kazuki Yasuda; Niels Grarup; Wei Zhao; Xu Wang; Alicia Huerta-Chagoya; Cheng Hu; Sanghoon Moon; Jirong Long; Soo Heon Kwak; Asif Rasheed; Richa Saxena; Ronald C W Ma; Yukinori Okada; Minoru Iwata; Jun Hosoe; Nobuhiro Shojima; Minaka Iwasaki; Hayato Fujita; Ken Suzuki; John Danesh; Torben Jørgensen; Marit E Jørgensen; Daniel R Witte; Ivan Brandslund; Cramer Christensen; Torben Hansen; Josep M Mercader; Jason Flannick; Hortensia Moreno-Macías; Noël P Burtt; Rong Zhang; Young Jin Kim; Wei Zheng; Jai Rup Singh; Claudia H T Tam; Hiroshi Hirose; Hiroshi Maegawa; Chikako Ito; Kohei Kaku; Hirotaka Watada; Yasushi Tanaka; Kazuyuki Tobe; Ryuzo Kawamori; Michiaki Kubo; Yoon Shin Cho; Juliana C N Chan; Dharambir Sanghera; Philippe Frossard; Kyong Soo Park; Xiao-Ou Shu; Bong-Jo Kim; Jose C Florez; Teresa Tusié-Luna; Weiping Jia; E Shyong Tai; Oluf Pedersen; Danish Saleheen; Shiro Maeda; Takashi Kadowaki
Journal:  Nat Commun       Date:  2016-01-28       Impact factor: 14.919

10.  Probing the catalytic functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524.

Authors:  Anna P Baron; Conrad von Schubert; Fabien Cubizolles; Gerhard Siemeister; Marion Hitchcock; Anne Mengel; Jens Schröder; Amaury Fernández-Montalván; Franz von Nussbaum; Dominik Mumberg; Erich A Nigg
Journal:  Elife       Date:  2016-02-17       Impact factor: 8.140
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.